Your browser doesn't support javascript.
loading
O-GlcNAc Modification Is a Promising Therapeutic Target for Diabetic Retinopathy.
Dong, Wenkang; Imdad, Laraib; Xu, Shengnan; Wang, Yinli; Liu, Chengzhi; Song, Shiyu; Li, Zechuan; Kong, Ying; Kong, Li; Ren, Xiang.
Afiliación
  • Dong W; Department of Histology and Embryology, College of Basic Medicine, Dalian Medical University, Dalian 116044, China.
  • Imdad L; Department of Histology and Embryology, College of Basic Medicine, Dalian Medical University, Dalian 116044, China.
  • Xu S; Department of Histology and Embryology, College of Basic Medicine, Dalian Medical University, Dalian 116044, China.
  • Wang Y; Department of Histology and Embryology, College of Basic Medicine, Dalian Medical University, Dalian 116044, China.
  • Liu C; Department of Histology and Embryology, College of Basic Medicine, Dalian Medical University, Dalian 116044, China.
  • Song S; Department of Histology and Embryology, College of Basic Medicine, Dalian Medical University, Dalian 116044, China.
  • Li Z; Department of Histology and Embryology, College of Basic Medicine, Dalian Medical University, Dalian 116044, China.
  • Kong Y; Key Laboratory of Reproductive and Developmental Biology, Dalian Medical University, Dalian 116044, China.
  • Kong L; Core Laboratory of Glycobiology and Glycoengineering, College of Basic Medical Sciences, Dalian Medical University, Dalian 116044, China.
  • Ren X; Department of Histology and Embryology, College of Basic Medicine, Dalian Medical University, Dalian 116044, China.
Int J Mol Sci ; 25(11)2024 Jun 06.
Article en En | MEDLINE | ID: mdl-38892474
ABSTRACT
Diabetic retinopathy (DR) is a very serious diabetes complication. Changes in the O-linked N-acetylglucosamine (O-GlcNAc) modification are associated with many diseases. However, its role in DR is not fully understood. In this research, we explored the effect of O-GlcNAc modification regulation by activating AMP-activated protein kinase (AMPK) in DR, providing some evidence for clinical DR treatment in the future. Bioinformatics was used to make predictions from the database, which were validated using the serum samples of diabetic patients. As an in vivo model, diabetic mice were induced using streptozotocin (STZ) injection with/without an AMPK agonist (metformin) or an AMPK inhibitor (compound C) treatment. Electroretinogram (ERG) and H&E staining were used to evaluate the retinal functional and morphological changes. In vitro, 661 w cells were exposed to high-glucose conditions, with or without metformin treatment. Apoptosis was evaluated using TUNEL staining. The protein expression was detected using Western blot and immunofluorescence staining. The angiogenesis ability was detected using a tube formation assay. The levels of O-GlcNAc transferase (OGT) and O-GlcNAcase (OGA) in the serum changed in the DR patients in the clinic. In the diabetic mice, the ERG wave amplitude and retinal thickness decreased. In vitro, the apoptotic cell percentage and Bax expression were increased, and Bcl2 expression was decreased in the 661 w cells under high-glucose conditions. The O-GlcNAc modification was increased in DR. In addition, the expression of GFAT/TXNIP O-GlcNAc was also increased in the 661 w cells after the high-glucose treatment. Additionally, the Co-immunoprecipitation(CO-IP) results show that TXNIP interacted with the O-GlcNAc modification. However, AMPK activation ameliorated this effect. We also found that silencing the AMPKα1 subunit reversed this process. In addition, the conditioned medium of the 661 w cells may have affected the tube formation in vitro. Taken together, O-GlcNAc modification was increased in DR with photoreceptor cell degeneration and neovascularization; however, it was reversed after activating AMPK. The underlying mechanism is linked to the GFAT/TXNIP-O-GlcNAc modification signaling axis. Therefore, the AMPKα1 subunit plays a vital role in the process.
Asunto(s)
Palabras clave

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Acetilglucosamina / N-Acetilglucosaminiltransferasas / Diabetes Mellitus Experimental / Retinopatía Diabética / Proteínas Quinasas Activadas por AMP Idioma: En Revista: Int J Mol Sci Año: 2024 Tipo del documento: Article

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Acetilglucosamina / N-Acetilglucosaminiltransferasas / Diabetes Mellitus Experimental / Retinopatía Diabética / Proteínas Quinasas Activadas por AMP Idioma: En Revista: Int J Mol Sci Año: 2024 Tipo del documento: Article